AIM ImmunoTech (AIM) Price & Analysis

Compare

908 Followers

AIM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.33 - $37.83

Previous CloseN/A

Volume272.06K

Average Volume (3M)319.45K

Market Cap

$6.99M

Enterprise Value$8.54M

Total Cash (Recent Filing)$835.00K

Total Debt (Recent Filing)$2.81M

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Nov 14, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.68

Shares Outstanding2,708,688

10 Day Avg. Volume62,054

30 Day Avg. Volume319,450

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.22

Enterprise Value/Revenue70.56

Enterprise Value/Gross Profit59.29

Enterprise Value/Ebitda-0.56

Forecast

1Y Price Target

$2.50

Price Target Upside0.00%

Rating ConsensusModerate Sell

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Analyst RatingThe analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.

Clinical TrialsPositive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.

Bears Say

Corporate GovernanceDissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.

Stock ListingThe company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.

AIM ImmunoTech News

AIM ImmunoTech releases CEO Corner segment

AIM ImmunoTech (AIM) announced the next CEO Corner segment has been published on the Company’s website. In this...

8d ago

AIM

AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year

As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000. “Through the second...

14d ago

AIM

AIM ImmunoTech announces four presentations on Ampligen at MSCI MSCS-2025

AIM ImmunoTech (AIM) announced that the clinical successes in oncology of its drug Ampligen will be presented in...

23d ago

AIM

AIM ImmunoTech highlights recent key financial milestones

AIM ImmunoTech (AIM) highlighted recent key financial milestones and firmly stated its focus on advancing clinical trials of...

25d ago

AIM

AZN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

30d ago

AIM

AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials

Aim Immunotech Inc. ( ($AIM) ) has released its Q2 earnings. Here is a breakdown of the information...

14d ago

AIM

AIM ImmunoTech Closes $8 Million Public Offering

AIM ImmunoTech ( ($AIM) ) has issued an announcement. On July 31, 2025, AIM ImmunoTech Inc. announced the...

28d ago

AIM

Why Is AIM ImmunoTech Stock (AIM) Down 50% Today?

AIM ImmunoTech stock dove on Tuesday after the company priced a public offering for its shares. ...

1M ago

AIM

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Earnings season is in full swing and TipRanks is home to all of the hottest coverage. ...

1M ago

AIM ImmunoTech prices 2M shares at $4.00 in public offering

AIM ImmunoTech (AIM) announced the pricing of a public offering of an aggregate of 2,000,000 shares of its...

1M ago

AIM

AIM ImmunoTech Reports Positive Phase 2 Study Results

The latest update is out from AIM ImmunoTech ( ($AIM) ). On July 28, 2025, AIM ImmunoTech Inc....

1M ago

AIM

AIM ImmunoTech Inc trading resumes

09:36 EDT AIM ImmunoTech (AIM) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

1M ago

AIM

AIM ImmunoTech Inc trading halted, volatility trading pause

09:31 EDT AIM ImmunoTech (AIM) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

1M ago

AIM

AIM ImmunoTech reports mid-year update from Phase 2 study of Aimpligen, Imfinzi

AIM ImmunoTech (AIM) reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating...

1M ago

AIM

AIM FAQ

What was AIM ImmunoTech’s price range in the past 12 months?

AIM ImmunoTech lowest stock price was $2.33 and its highest was $37.83 in the past 12 months.

What is AIM ImmunoTech’s market cap?

AIM ImmunoTech’s market cap is $6.99M.

When is AIM ImmunoTech’s upcoming earnings report date?

AIM ImmunoTech’s upcoming earnings report date is Nov 14, 2025 which is in 77 days.

How were AIM ImmunoTech’s earnings last quarter?

AIM ImmunoTech released its earnings results on Aug 15, 2025. The company reported -$3.68 earnings per share for the quarter, beating the consensus estimate of -$8 by $4.32.

Is AIM ImmunoTech overvalued?

According to Wall Street analysts AIM ImmunoTech’s price is currently same. Get more investment ideas with TipRanks Premium

Does AIM ImmunoTech pay dividends?

AIM ImmunoTech pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here

What is AIM ImmunoTech’s EPS estimate?

AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AIM ImmunoTech have?

AIM ImmunoTech has 2,708,688 shares outstanding.

What happened to AIM ImmunoTech’s price movement after its last earnings report?

AIM ImmunoTech reported an EPS of -$3.68 in its last earnings report, beating expectations of -$8. Following the earnings report the stock price went up 3.113%.

Which hedge fund is a major shareholder of AIM ImmunoTech?

Currently, no hedge funds are holding shares in AIM

Company Description

AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech (AIM) Earnings & Revenues

Historic Earnings Reports

AIM Stock 12 Month Forecast

Average Price Target

$2.50

▲(0.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","17":"$17","33":"$33","49":"$49","65":"$65"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,17,33,49,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,2.8046153846153845,2.7792307692307694,2.753846153846154,2.7284615384615387,2.703076923076923,2.6776923076923076,2.6523076923076925,2.626923076923077,2.6015384615384614,2.5761538461538462,2.5507692307692307,2.5253846153846156,{"y":2.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,2.8046153846153845,2.7792307692307694,2.753846153846154,2.7284615384615387,2.703076923076923,2.6776923076923076,2.6523076923076925,2.626923076923077,2.6015384615384614,2.5761538461538462,2.5507692307692307,2.5253846153846156,{"y":2.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,2.8046153846153845,2.7792307692307694,2.753846153846154,2.7284615384615387,2.703076923076923,2.6776923076923076,2.6523076923076925,2.626923076923077,2.6015384615384614,2.5761538461538462,2.5507692307692307,2.5253846153846156,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.1,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.3,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.5,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.01,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.11,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >